Clinical Innovation Partnerships 2018
When: 03 – 04 July, 2018 Where: Radisson Blu Hotel, Zurich Airport The only event for senior Clinical Operations and…
Bionomics begins phase II clinical trial of drug for treating agitation
Bionomics will recruit about 40 elderly patients in specialist geriatric hospital wards across Australia. Bionomics Ltd (ASX:BNO) has commenced a…
VFMCRP AND CARA THERAPEUTICS TO DEVELOP AND COMMERCIALISE CR845 INJECTION FOR CHRONIC KIDNEY DISEASE-ASSOCIATED PRURITUS
Vifor Fresenius Medical Care Renal Pharma (VFMCRP) to develop and commercialise CR845/difelikefalin injection worldwide except in the US, Japan and…
Researchers Develop Diagnostic for Rare Cancer-Generated Glycoproteins
Engineered chemical trap detects rare glycoproteins emitted as cancer first develops. Researchers at the Georgia Institute of Technology have designed…
Jeil Pharma unveils new research centre
The new research centre is part of the company’s plans to strengthen investment in the R&D sector. Jeil Pharmaceutical has…
Rapid Medical initiates TIGER Clinical Study
Data from the study will be submitted to the FDA in support of Market Clearance for TIGERTRIEVER in the U.S.…
Ultragenyx and Kyowa Kirin Announce Topline Phase 3 Study Results Demonstrating Superiority of Crysvita® (burosumab) Treatment to Oral Phosphate and Active Vitamin D in Children with X-Linked Hypophosphatemia (XLH)
Substantial Healing of Rickets Observed in 72% of Patients Treated with Crysvita Compared to 6% of Patients Receiving Conventional Therapy…
Healthcare IT business Trialbee pursues strategic expansion through new talent and investment
Swedish clinical trial technology firm Trialbee announces the appointment of several new senior leadership positions and new investments. This injection…
New England Journal of Medicine publishes two positive Phase 3 trials showing Dupixent® (dupilumab) improved moderate-to-severe asthma
Results showed Dupixent demonstrated a significant improvement in multiple asthma endpoints in two Phase 3 clinical trials in a broad…
XBiotech Announces First Patient in Phase 2 Study Evaluating MABp1 in Patients with Atopic Dermatitis
First Patient Begins Therapy with MABp1 for Treatment of Atopic Dermatitis XBiotech Inc. (NASDAQ:XBIT) announced today that the first patient…